

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Melanoma	Phosphoinositide 3-kinase (PI3K)	<p>Mouse and cell culture studies suggest inhibiting PI3K signaling could help improve the effects of ADI-PEG 20 in melanoma. In a human melanoma cell line, ADI-PEG 20 plus either of two PI3K inhibitors decreased proliferation compared with each compound alone. In a mouse xenograft model of melanoma, ADI-PEG 20 plus a PI3K inhibitor lowered tumor volumes compared with either compound alone. Next steps could include evaluating the combination approach in additional melanoma models. ADI-PEG 20, an arginine deiminase (ADI) formulated with polyethylene glycol from Polaris Pharmaceuticals Inc., is in Phase II/III trials to treat multiple cancers.</p> <p><i>SciBX</i> 5(17); doi:10.1038/scibx.2012.437 Published online April 26, 2012</p>	Patent and licensing status unavailable	<p>Tsai, W.-B. <i>et al. Cancer Res.</i>; published online March 29, 2012; doi:10.1158/0008-5472.CAN-11-3605 Contact: Macus Tien Kuo, The University of Texas MD Anderson Cancer Center, Houston, Texas e-mail: tkuo@mdanderson.org</p>